Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis
Authors
Keywords
-
Journal
Science Advances
Volume 4, Issue 11, Pages eaat3834
Publisher
American Association for the Advancement of Science (AAAS)
Online
2018-11-29
DOI
10.1126/sciadv.aat3834
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Thrombopoietin receptor is required for the oncogenic function of CALR mutants
- (2016) H Nivarthi et al. LEUKEMIA
- Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin
- (2016) T Balligand et al. LEUKEMIA
- Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis
- (2015) C. Marty et al. BLOOD
- CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms
- (2015) Sara C. Meyer et al. CANCER CELL
- Leukemic Diffuse Large B-Cell Lymphoma in a Patient With Myeloproliferative Disorder
- (2015) Vijaya Raj Bhatt et al. Journal of the National Comprehensive Cancer Network
- Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors
- (2014) S. C. Meyer et al. CLINICAL CANCER RESEARCH
- Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation
- (2014) Yan Beauverd et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Mechanism of Activation of Protein Kinase JAK2 by the Growth Hormone Receptor
- (2014) A. J. Brooks et al. SCIENCE
- Ruxolitinib Withdrawal Syndrome Leading to Tumor Lysis
- (2013) Tong Dai et al. JOURNAL OF CLINICAL ONCOLOGY
- Janus Kinase Deregulation in Leukemia and Lymphoma
- (2012) Edwin Chen et al. IMMUNITY
- The JAK-STAT Pathway at Twenty
- (2012) George R. Stark et al. IMMUNITY
- Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
- (2012) Priya Koppikar et al. NATURE
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent
- (2012) Rita Andraos et al. Cancer Discovery
- Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis
- (2011) Ayalew Tefferi et al. MAYO CLINIC PROCEEDINGS
- Effective Suppression of Vascular Network Formation by Combination of Antibodies Blocking VEGFR Ligand Binding and Receptor Dimerization
- (2010) Denis Tvorogov et al. CANCER CELL
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started